Betoptic
(Betaxolol)Phase 3Small molecule
SanofiBetoptic is one of 51 small molecule programs targeting Glaucoma. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
50
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
182 competitors in Glaucoma
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Namenda
AbbViePhase 3
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Tocopherol
MM.D. Anderson Cancer Center
Phase 3
Betoptic
SanofiPhase 3
LUMIGAN
AbbViePhase 3
TFC-003
KKukje Pharma
Phase 3
Prostaglandin
LLaboratoires Thea
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Aug 30, 1985
BETOPTIC
NDA NDA019270
Oct 27, 1989
KERLONE
NDA NDA019507
Dec 29, 1989
BETOPTIC S
NDA NDA019845
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Betaxolol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]